In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Legend Biotech Corp (NASDAQ:LEGN) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with ...

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

On Friday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $40.03 which represents a decrease of $-0.92 or -2.25% from the prior close of $40.95. The stock opened at $40.61 and ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Legend Biotech (NASDAQ:LEGN) is scheduled to announce Q3 earnings results on Tuesday, November 12th, before market open. The consensus EPS Estimate is -$0.57 and the consensus Revenue Estimate is $146 ...

Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), and a leader in automated cell therapy manufacturing, has appointed Ossama Eissa, former executive at Novartis ...

Lawmakers request intelligence briefing on CDMO GenScript, Legend Biotech's ties to China In June, committee chairman John Moolenaar, R-Michigan, and ranking member Raja Krishnamoorthi, D-Illinois, ...